Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165243 | 0.90 | BRD4 (0.49) | BRD4PTPN11ACVR1KITMAPT | |
| SCHEMBL17282544 | 0.87 | BRD4 (0.50) | BRD4PTPN11KITMAPTMAP4K1 | |
| SCHEMBL15556465 | 0.85 | BRD4 (0.49) | BRD4PTPN11ACVR1KITMAPT | |
| SCHEMBL1850782 | 0.83 | BRD4 (0.64) | BRD4PTPN11MAPTALDH1A1KDM4E | |
| SCHEMBL29086638 | 0.82 | BRD4 (0.43) | BRD4PTPN11ALDH1A1KMT2AMEN1 | |
| SCHEMBL15555565 | 0.82 | BRD4 (0.46) | BRD4PTPN11MAPTKMT2ACYP3A4 | |
| SCHEMBL15555568 | 0.82 | BRD4 (0.46) | BRD4PTPN11KITMAP4K1POLB | |
| SCHEMBL2279727 | 0.82 | JAK2 (0.44) | BRD4ACVR1MAPTALDH1A1KDM4E | |
| SCHEMBL15556952 | 0.82 | BRD4 (0.44) | BRD4PTPN11FYNACVR1KIT | |
| SCHEMBL1372485 | 0.82 | BRD4 (0.49) | BRD4PTPN11MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| EP-3037421-A1 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-3037421-A1 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-01-28 | — | — | US | disclosed |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-01-28 | — | — | US | disclosed |
| US-9181247-B2 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2015-11-10 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2576549-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | University of Rochester (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2379561-A2 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | BRD4 806/4885PTPN11 1375/4885FYN 567/4885 |
| US-20130203755-A1 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | MAP2K2, MAP2K7, CHKB | BRD4 583/4885PTPN11 1949/4885FYN 394/4885 |
| US-20160024087-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | BRD4 806/4885PTPN11 1375/4885FYN 567/4885 |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | BRD4 806/4885PTPN11 1375/4885FYN 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.